webinar register page

Webinar banner
RedChip Investor Group Call with Reviva Pharmaceuticals (NASDAQ: RVPH)
Reviva is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.


Webinar logo
* Required information


Laxminarayan Bhat, PhD
Founder, President and Chief Executive Officer @Reviva Pharmaceutical Holdings, Inc.
Dr. Bhat founded Reviva Pharmaceuticals in 2006 and since its inception, Reviva has advanced rapidly under his leadership, with a portfolio of proprietary compounds at different stages in a pipeline encompassing chronic diseases in the central nervous system, respiratory, and metabolic diseases. Dr. Bhat has developed and implemented innovative financing and business models with strategies that have greatly accelerated the drug discovery and development process, resulting in significant savings of time and costs but without sacrificing quality.